儿童患者万古霉素群体药代动力学模型的系统评价
多数研究采用一室模型,清除率和分布容积个体间变异大,清除率显著协变量为体重、年龄、血清肌酐或肌酐清除率,分布容积为体重;结论认为仍需外部验证及亚组人群模型。
要点
- 儿童万古霉素群体药代动力学模型多为一室模型,清除率与分布容积个体间变异大。
- 清除率显著协变量为体重、年龄、血清肌酐或肌酐清除率,分布容积为体重。
- 现有模型推荐剂量不一,用于 dosing 前需外部验证并补充透析等亚组人群模型。
核心结论
- 已建立众多儿童万古霉素群体药代动力学模型,但推荐剂量方案尚需外部验证及透析等亚组人群分析后才能用于给药推荐。
- 儿童万古霉素存在显著的个体内和个体间药代动力学变异,提示需要持续进行治疗药物监测,并为特定亚组人群(如透析患者)建立药代动力学模型。
研究设计与样本
- 系统检索Cochrane CENTRAL、MEDLINE、EMBASE、International Pharmaceutical Abstracts及灰色文献,无语言或发表状态限制,检索至2020年8月17日。
- 偏倚风险采用National Heart, Lung and Blood Institute的病例系列研究质量评估工具进行评估。
主要发现
- 纳入患者平均年龄2.5岁(范围1天至18岁),血清肌酐47.1 ± 33.6 µmol/L,估算肌酐清除率97.4 ± 76 mL/min/1.73m²。
- 71.9%的研究认为万古霉素药代动力学最佳描述为一室模型。
- 清除率范围为0.014–0.27 L/kg/h,分布容积范围为0.43–1.46 L/kg;清除率个体间变异最高达49.7%,分布容积个体间变异最高达136%。
- 比例残差变异最高达37.5%,加和残差变异最高达17.5 mg/L。
- 清除率最显著的协变量为体重、年龄、血清肌酐或肌酐清除率,分布容积最显著的协变量为体重;各研究报告的剂量推荐不一。
临床怎么用
- 临床可参考体重、年龄、血清肌酐或肌酐清除率等协变量个体化评估儿童万古霉素清除率,参考体重评估分布容积。
- 鉴于个体内和个体间药代动力学变异显著,应持续进行治疗药物监测。
- 现有模型推荐剂量不一,在应用最佳预测性能模型进行给药推荐前需等待外部验证及亚组人群分析结果。
局限性
- 推荐剂量方案尚需外部验证,且缺乏透析患者等亚组儿童人群的分析。
- 纳入研究以回顾性研究为主(50项),证据受研究设计限制。
- 各研究报告的剂量推荐不一致,尚无法确定最佳预测性能的群体药代动力学模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is commonly used to treat gram-positive bacterial infections in the paediatric population, but dosing can be challenging. Population pharmacokinetic (popPK) modelling can improve individualization of dosing regimens. The primary objective of this study was to describe popPK models of vancomycin and factors that influence pharmacokinetic (PK) variability in paediatric patients. METHODS: Systematic searches were conducted in the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, International Pharmaceutical Abstracts and the grey literature without language or publication status restrictions from inception to 17 August 2020. Observational studies that described the development of popPK models of vancomycin in paediatric patients (< 18 years of age) were included. Risk of bias was assessed using the National Heart, Lung and Blood Institute Study Quality Assessment Tool for Case Series Studies. RESULTS: Sixty-four observational studies (1 randomized controlled trial, 13 prospective studies and 50 retrospective studies of 9019 patients with at least 25,769 serum vancomycin concentrations) were included. The mean age was 2.5 years (range 1 day-18 years), serum creatinine was 47.1 ± 33.6 µmol/L, and estimated creatinine clearance was 97.4 ± 76 mL/min/1.73m2. Most studies found that vancomycin PK was best described by a one-compartment model (71.9%). There was a wide range of clearance and volume of distribution (Vd) values (range 0.014-0.27 L/kg/h and 0.43-1.46 L/kg, respectively) with interindividual variability as high as 49.7% for clearance and 136% for Vd, proportional residual variability up to 37.5% and additive residual variability up to 17.5 mg/L. The most significant covariates for clearance were weight, age, and serum creatinine or creatinine clearance, and weight for Vd. Variable dosing recommendations were suggested. CONCLUSION: Numerous popPK models of vancomycin were derived, however external validation of suggested dosing regimens and analyses in subgroup paediatric populations such as dialysis patients are still needed before a popPK model with best predictive performance can be applied for dosing recommendations. Significant intraindividual and interindividual PK variability was present, which demonstrated the need for ongoing therapeutic drug monitoring and derivation of PK models for vancomycin for certain subgroup populations, such as dialysis patients.
引用
- Chung E, Sen J, Patel P, et al. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet. 2021. PMID: 34002357. doi:10.1007/s40262-021-01027-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。